Bristol-Myers Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 9/6/2026)
| Balance Sheet | Total Assets | 90,038,000,000.00 | ROE | 20.52 % |
| Balance Sheet | Total Equity | 18,505,000,000.00 | ROA | 7.83 % |
| Cashflow | Capital Expenditures | -1,311,000,000.00 | P/FCF | 9.42 |
| Cashflow | Free Cash Flow | 12,844,999,680.00 | – | – |
| Cashflow | Operating Cash Flow | 13,685,000,000.00 | P/CF | 8.55 |
| Income | Earnings per Share (diluted) | 3.46 | Div. Yield | 4.20 % |
| Income | Net Income | 7,053,000,000.00 | P/E | 17.13 |
| Income | Shares Outstanding | 2,041,000,000.00 | P/B | 6.55 |
| Income | Total Revenue | 48,194,000,000.00 | P/S | 2.51 |
Ratios calculated on: 10/14/2026
Company Description
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. It operates in BioPharmaceuticals. Its products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States (U.S.), Puerto Rico and in 6 foreign countries. In February 2012, it acquired Inhibitex, Inc. (Inhibitex). In August 2012, the Company announced the acquisition of Amylin Pharmaceuticals, Inc. In August 2012, Synergy Pharmaceuticals Inc announced that it signed an Asset Purchase Agreement with the Company and acquired the assets related to FV-100, an orally available nucleoside analogue, being developed for the treatment of shingles.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.bms.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more